ARQT logo

Arcutis Biotherapeutics (ARQT) Cash from financing

annual CFF:

$66.20M-$35.12M(-34.66%)
December 31, 2024

Summary

  • As of today (May 24, 2025), ARQT annual cash flow from financing activities is $66.20 million, with the most recent change of -$35.12 million (-34.66%) on December 31, 2024.
  • During the last 3 years, ARQT annual CFF has fallen by -$215.75 million (-76.52%).
  • ARQT annual CFF is now -78.06% below its all-time high of $301.80 million, reached on December 31, 2022.

Performance

ARQT Cash from financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherARQTcash flow metrics

quarterly CFF:

$395.00K+$97.81M(+100.41%)
March 31, 2025

Summary

  • As of today (May 24, 2025), ARQT quarterly cash flow from financing activities is $395.00 thousand, with the most recent change of +$97.81 million (+100.41%) on March 31, 2025.
  • Over the past year, ARQT quarterly CFF has dropped by -$161.37 million (-99.76%).
  • ARQT quarterly CFF is now -99.86% below its all-time high of $284.99 million, reached on September 30, 2022.

Performance

ARQT quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherARQTcash flow metrics

TTM CFF:

-$95.17M-$161.37M(-243.75%)
March 31, 2025

Summary

  • As of today (May 24, 2025), ARQT TTM cash flow from financing activities is -$95.17 million, with the most recent change of -$161.37 million (-243.75%) on March 31, 2025.
  • Over the past year, ARQT TTM CFF has dropped by -$358.15 million (-136.19%).
  • ARQT TTM CFF is now -125.46% below its all-time high of $373.72 million, reached on September 30, 2022.

Performance

ARQT TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherARQTcash flow metrics

Cash from financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

ARQT Cash from financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-34.7%-99.8%-136.2%
3 y3 years-76.5%-97.3%-207.1%
5 y5 years-28.9%-99.8%-136.3%

ARQT Cash from financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-78.1%at low-99.9%+100.4%-125.5%at low
5 y5-year-78.1%at low-99.9%+100.4%-125.5%at low
alltimeall time-78.1%+829.9%-99.9%+100.4%-125.5%at low

ARQT Cash from financing History

DateAnnualQuarterlyTTM
Mar 2025
-
$395.00K(-100.4%)
-$95.17M(-243.8%)
Dec 2024
$66.20M(-34.7%)
-$97.41M(<-9900.0%)
$66.20M(-74.8%)
Sep 2024
-
$394.00K(-72.9%)
$262.90M(-0.2%)
Jun 2024
-
$1.46M(-99.1%)
$263.38M(+0.1%)
Mar 2024
-
$161.76M(+62.9%)
$262.99M(+159.6%)
Dec 2023
$101.32M(-66.4%)
$99.29M(>+9900.0%)
$101.32M(+3281.9%)
Sep 2023
-
$867.00K(-18.7%)
$3.00M(-99.0%)
Jun 2023
-
$1.07M(+967.0%)
$287.12M(-0.0%)
Mar 2023
-
$100.00K(-89.6%)
$287.18M(-4.8%)
Dec 2022
$301.80M(+7.0%)
$962.00K(-99.7%)
$301.80M(-19.2%)
Sep 2022
-
$284.99M(>+9900.0%)
$373.72M(+320.9%)
Jun 2022
-
$1.13M(-92.3%)
$88.79M(-0.1%)
Mar 2022
-
$14.72M(-79.8%)
$88.85M(-68.5%)
DateAnnualQuarterlyTTM
Dec 2021
$281.95M(-5.4%)
$72.88M(>+9900.0%)
$281.95M(-16.7%)
Sep 2021
-
$63.00K(-94.7%)
$338.45M(+0.1%)
Jun 2021
-
$1.19M(-99.4%)
$337.95M(+0.3%)
Mar 2021
-
$207.81M(+60.6%)
$337.07M(+13.1%)
Dec 2020
$298.14M(+220.2%)
$129.38M(<-9900.0%)
$298.14M(+13.9%)
Sep 2020
-
-$437.00K(-241.4%)
$261.72M(-0.2%)
Jun 2020
-
$309.00K(-99.8%)
$262.14M(+0.1%)
Mar 2020
-
$168.89M(+81.7%)
$262.00M(+181.4%)
Dec 2019
$93.10M(+51.2%)
$92.95M(<-9900.0%)
$93.10M(>+9900.0%)
Sep 2019
-
-$20.00K(-111.9%)
$148.00K(-11.9%)
Jun 2019
-
$168.00K(>+9900.0%)
$168.00K(>+9900.0%)
Mar 2019
-
$0.00
$0.00
Dec 2018
$61.59M(+765.2%)
-
-
Dec 2017
$7.12M
-
-

FAQ

  • What is Arcutis Biotherapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for Arcutis Biotherapeutics?
  • What is Arcutis Biotherapeutics annual CFF year-on-year change?
  • What is Arcutis Biotherapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Arcutis Biotherapeutics?
  • What is Arcutis Biotherapeutics quarterly CFF year-on-year change?
  • What is Arcutis Biotherapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Arcutis Biotherapeutics?
  • What is Arcutis Biotherapeutics TTM CFF year-on-year change?

What is Arcutis Biotherapeutics annual cash flow from financing activities?

The current annual CFF of ARQT is $66.20M

What is the all time high annual CFF for Arcutis Biotherapeutics?

Arcutis Biotherapeutics all-time high annual cash flow from financing activities is $301.80M

What is Arcutis Biotherapeutics annual CFF year-on-year change?

Over the past year, ARQT annual cash flow from financing activities has changed by -$35.12M (-34.66%)

What is Arcutis Biotherapeutics quarterly cash flow from financing activities?

The current quarterly CFF of ARQT is $395.00K

What is the all time high quarterly CFF for Arcutis Biotherapeutics?

Arcutis Biotherapeutics all-time high quarterly cash flow from financing activities is $284.99M

What is Arcutis Biotherapeutics quarterly CFF year-on-year change?

Over the past year, ARQT quarterly cash flow from financing activities has changed by -$161.37M (-99.76%)

What is Arcutis Biotherapeutics TTM cash flow from financing activities?

The current TTM CFF of ARQT is -$95.17M

What is the all time high TTM CFF for Arcutis Biotherapeutics?

Arcutis Biotherapeutics all-time high TTM cash flow from financing activities is $373.72M

What is Arcutis Biotherapeutics TTM CFF year-on-year change?

Over the past year, ARQT TTM cash flow from financing activities has changed by -$358.15M (-136.19%)
On this page